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Abstract 
 
The results on solubilization of poorly water-soluble drugs, 
indomethacin, piroxicam, and meloxicam, with the help of 
mechanochemical methods are presented. The mechano-
composites of the drugs with various excipients, including soluble 
polymers and non-soluble fine porous inorganic oxides, were 
obtained by co-grinding using vibrational and planetary 
centrifugal mills. The samples obtained revealed higher release 
rate and apparent solubility of the drugs with respect to the initial 
ones. Nevertheless, in some cases, e.g. for composites of 
piroxicam with alumina and ferric oxide, decreasing the release 
rate and solubility of the drug was observed suggesting the 
formation of poorly soluble strong drug - carrier associates. 
 
Introduction 
 
Improvement in the extent and rate of dissolution of poorly water-
soluble drugs is highly desirable as this can lead to an increased 
and more reproducible oral bioavailability. During the past four 
decades, there was a great interest in solid dispersion systems to 
increase dissolution rate and bioavailability of poorly soluble 
drugs [1]. Mechanochemical treatment was proposed by Nakai in 
1974 [2] as an efficient method to prepare solid dispersions of 
drugs. Disordering and amorphisation of the drug upon grinding 
results in enhanced apparent solubility [3]. As a result of co-
grinding drug - carrier mixtures, the formation of the particles 
smaller than 100 nm in diameter, or appearance of the distributed 
thin layer on the surface of the particles of drugs larger than 100 
nm in diameter is possible leading to formation of micro- or 
nanocomposites [4, 5]. The composites obtained are characterized 
by special properties such as enhanced dissolution rate and 
solubility of the drug [6].  
 
The purpose of this work was to study solubilization of poorly 
water-soluble non-steroidal anti-inflammatory drugs, namely, 
piroxicam, meloxicam, and indomethacin, with the help of 
mechanochemical methods. Various excipients including soluble 
polymers and non-soluble fine porous inorganic oxides were used 
to prepare mechanocomposites of the drugs.  
 
Experimental 
 
Vibrational [SPEX 8000 (USA)] and planetary centrifugal [AGO-
2 (Russia)] mills were used for co-grinding. The 1:1, 1:3 and 1:10 
drug-carrier mixtures were prepared. Time of treatment varied 
from 10 to 30 minutes. The properties of the mechanocomposites 
obtained were studied by the X-ray diffraction and IR 
spectroscopy methods. X-ray powder diffraction (XRPD) patterns 
were measured with a D8 DISCOVER GADDS diffractometer 
(Bruker, Germany) with СuKα radiation. IR spectra were recorded 
with Infralum FT-801 FTIR spectrometer (Russia) in tablet with 
KBr. Attenuated total reflectance infrared spectroscopy (ATR) 
was performed with Digilab Excalibur 3100 FTIR spectrometer 
(Varian, USA).  
 
To measure the dissolution, solubility tester Varian 705 DS was 
used. A weighed portion of the sample, with the particle size of 
125-315 µm, containing the drug in excess, was put into a glass 
vessel containing distilled water at 37±0.5oС. After definite time 
intervals, the concentration of the substance in solution was 
measured with a Carry 50 spectrophotometer.  
 
Results 
 
Solid Dispersion Systems of Piroxicam and Indomethacin with 
Polymers 
  
The mechanocomposites of piroxicam and indomethacin with 
polyvinylpyrrolidone (PVP) and polyethylene glycol (PEG) were 
prepared by co-grinding. In the case of composites with PVP, the 
X-ray amorphous products were obtained. The changes in IR 
spectra suggested the interaction between the components due to 
formation of hydrogen bonds. The piroxicam – PVP 
mechanocomposites were characterized by increased rate of 
dissolution and solubility of the drug (Concentration (C) vs. time 
plots, Fig. 1). In Fig. 2, the dissolution curves for piroxicam – 
PEG mechanocomposites are presented. As a result of the 
interaction of the components under co-grinding, the increased 
rate of dissolution and solubility of piroxicam was observed in 
comparison with the physical mixture of the components.  
 
 
Figure 1. Dissolution curves of ball milled 1:1 (1) and 1:10 (2) 
(w/w) piroxicam – PVP mixtures, and piroxicam alone (3) 
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Figure 2. Dissolution curves of initial piroxicam (1); 1:1 (2) and 
1:10 (3) piroxicam – PEG physical mixtures; 1:1 (4), 1:3 (5), 1:10 
(6) piroxicam – PEG ball milled mixtures 
 
In addition to PVP and PEG, the polypropylene (PP) as an inert 
additive was used to prepare the mechanocomposites with 
indomethacin [7]. In Fig. 3, the dissolution curves of 
indomethacin for co-ground mixtures with PP are presented in 
comparison with those for indomethacin intact and its co-ground 
mixtures with PVP and PEG. It is seen that the presence of inert 
additive influenced on dissolution of the drug. In comparison with 
initial indomethacin, the higher concentration of the drug in 
solution was achieved probably due to dispersion of the drug 
within the carrier.  
 
Figure 3. Dissolution curves of indomethacin (1), ground 
indomethacin (2), mixtures of indomethacin with PP (3), PVP (4) 
and PEG (5) (1:3, w/w) 
 
The mechanocomposites of piroxicam with microcrystalline 
cellulose (MCC) revealed increased rate of dissolution of the drug 
(Fig. 4) [8]. The concentration of piroxicam in solution only 
slightly increased in comparison with ground piroxicam, 
nevertheless, the mechanocomposites, in contrast to drug alone, 
were more stable and preserve piroxicam in active form for a 
longer time. 
 
 
Figure 4. Dissolution curves of mechanically activated piroxicam 
(1), initial piroxicam (2), 1:1 (3) and 1:10 (4) piroxicam – MCC 
mixtures ball milled in SPEX mill 
 
Nanocomposites of piroxicam and indomethacin with inorganic 
oxides 
 
The nanocomposites of piroxicam and indomethacin with fine 
porous inorganic oxides, alumina, silica, and magnesia, containing 
the drugs in X-ray amorphous state were obtained by ball milling 
[9]. The changes in IR spectra suggested the interaction of the 
components under ball milling that led to stabilization of the drugs 
in the metastable state.  
 
In the case of co-ground mixtures of piroxicam with alumina, the 
apparent equilibrium solubility of the drug was lower than the 
solubility of the initial piroxicam (Fig. 5 (a), curve 3). The 
possible reason for decreasing the concentration of the drug in 
solution may be the formation of strong water-insoluble drug - 
carrier complexes at the surface of alumina. At the same time, in 
the case of indomethacin, all the samples revealed the drug 
solubility higher than that of the initial drug (Fig. 5(b), curve 3). 
These facts suggested a stronger interaction of piroxicam with 
alumina surface, compared to indomethacin. One of the possible 
reasons may be the formation of complexes of piroxicam 
employing the pyridyl nitrogen and the amide oxygen atoms of 
the drug. 
 
Mechanocomposites of piroxicam and indomethacin with silica 
revealed the higher apparent equilibrium solubility of the drugs 
than those of the initial ones (Fig. 5). For piroxicam - SiO2 
mixtures, solubility increased by a factor of 2; for 1:3 
indomethacin - SiO2 mixture treated in Spex 8000 mill for 30 min, 
solubility achieved 0.14 mg/ml, i.e. 28 times higher than that of 
the initial drug.  
 
In the case of piroxicam-based mechanocomposites with 
magnesia, the apparent equilibrium solubility of piroxicam was 
higher than that of the initial drug (Fig. 5(a), curve 5). As for 
indomethacin, the salt form of the drug was identified in the 
solution, the solubility was 80 times higher as compared to the 
initial drug. 
 
Nanocomposites of piroxicam with ferric oxide presented the 
particles of the oxide covered by a thin layer of the drug. The rate 
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of dissolution of the piroxicam was lower than that of the initial 
drug (Fig. 6) suggesting the formation of strong drug-carrier 
complexes at the surface of the oxide. 
 
 
(a) 
 
(b) 
Figure 5. Dissolution curves of (a) intact piroxicam (1), ball 
milled piroxicam alone (2), 1:3 piroxicam – oxide mixtures 
ground in the SPEX mill for 30 min: with Al2O3 (3), with SiO2 
(4), with MgO (5); (b) intact indomethacin (1), ball milled 
indomethacin alone (2), 1:3 indomethacin – oxide mixtures 
ground in the SPEX mill for 30 min: with Al2O3 (3), with SiO2 (4) 
 
Figure 6. Dissolution curves of initial piroxicam (1); 1:3 
piroxicam – ferric oxide mixture ground in SPEX mill for 15 min 
(2); piroxicam - ferric oxide mixture ground in AGO mill: 1:3, 30 
min (3), 1:10, 10 min (4) 
Mechanocomposites of Meloxicam with Excipients  
 
Solubilization of meloxicam with the help of mechanochemical 
methods was studied using excipients which were usually used in 
tabletted forms of meloxicam, namely, PVP, lactose, starch, 
magnesium stearate, sodium citrate. Polyethylene oxide (PEO), 
hydroxypropylmethylcellulose (HPMC), and chitosan were also 
used as carriers.  
 
In the case of PVP, the X-ray amorphous samples were obtained 
suggesting distribution of the drug within the polymer or 
formation of an amorphous product. The use of planetary 
centrifugal AGO-2 mill and increased content of the carrier were 
more preferable to obtain amorphous product. Co-grinding the 
mixtures of meloxicam with PEO, HPMC, MgSt, NaCit resulted 
in broadening of X-ray diffraction peaks and decreasing their 
intensity suggesting particle size reduction and partial disordering 
of crystal structure of meloxicam.  
 
The changes in IR spectra of the mixtures of meloxicam with 
PVP, HPMC, NaCit, and starch after mechanical treatment 
suggested the interaction of the components due to hydrogen 
bonds formation. The absence of changes in IR spectra of ball 
milled samples with PEO and magnesium stearate confirmed that 
there were no hydrogen bonding between the drug and excipient 
in these mixtures. 
 
The data on dissolution of meloxicam for the co-ground mixtures 
with the excipients are summarized in Table 1. It is seen that the 
samples obtained revealed the increasing solubility of the 
meloxicam compared to the initial drug.  
 
Table 1. Dissolution data for meloxicam in co-ground mixtures 
with excipients 
 
 
Excipient 
 
Apparent solubility, mg/ml 
 
  
- 0.03 
Starch 0.05 
Lactose 0.08 
Chitosan 0.08 
PEO 0.08 
HPMC 0.15 
PVP 0.25 
 Sodium citrate  0.60 
  
 
For the mixtures with PEO, all the samples obtained revealed the 
increased dissolution rate of meloxicam, nevertheless, the 
concentration of the drug in solution only slightly exceeded the 
solubility of the initial drug (Fig. 7). The curves with maximum 
were observed for which the high dissolution rate in the initial 
time was characteristic and then the concentration of the drug in 
solution decreased. The maximum apparent solubility equal to 
0.08 mg/ml was reached for the 1:3 meloxicam – PEO mixture co-
ground in AGO-2 mill.  
 
Mechanically activated mixtures of meloxicam with magnesium 
stearate revealed decreased rate of dissolution and solubility of the 
drug in comparison with the physical mixtures of the components 
(Fig. 7) suggesting encapsulating of the drug by carrier.  
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Figure 7. Dissolution curves of meloxicam with PEO and 
magnesium stearate (1:3, w/w): 1 - meloxicam initial; 2 – 
meloxicam - PEO physical mixture; 3 – meloxicam - PEO mixture 
co-ground in SPEX mill; 4 – meloxicam - PEO mixture co-ground 
in AGO mill; 5 - meloxicam – StMg physical mixture; 6 - 
meloxicam –MgSt mixture co-ground in AGO mill 
 
As an example, at the Fig. 8 the dissolution curves for the 
mechanocomposites of meloxicam with sodium citrate are 
presented. Based on the changes in X-ray diffraction patterns, it 
can be supposed that mechanical treatment of meloxicam in the 
mixtures with sodium citrate led to reduction of particle size and, 
depending on the conditions, to partial or total amorphization of 
the drug. The changes in IR spectra of the co-ground samples 
suggested interaction of the components due to intermolecular 
hydrogen bond formation between С=О groups of excipient and 
ОН- or NH-groups of meloxicam. For X-ray amorphous samples 
co-ground in AGO-2 mill for 15 min, the maximum was observed 
at the dissolution curve. The co-ground 1:3 meloxicam – sodium 
citrate mixture revealed apparent solubility higher than that of the 
initial drug in 20 times (Fig. 8, curve 5).  
 
Figure 8. Dissolution curves of the mixtures of meloxicam with 
sodium citrate (1:3, w/w): 1 – meloxicam initial; 2 – physical 
mixture; 3 – mixture of the components ball milled in AGO mill 
separately; 4 - 2:1 (mol.) meloxicam – NaCit mixture ball milled 
in SPEX mill with addition of ethanol; 5 - meloxicam – NaCit 
mixture ball milled in AGO mill 
 
Discussion and Conclusions 
 
Thus, it has been shown that ball milling of poorly water-soluble 
drugs, indomethacin, piroxicam, meloxicam, with different 
excipients resulted in increasing the rate of dissolution of the 
drugs and ther concentration in solution that can be possibly used 
for enhancing oral bioavailability.  
 
It is known that high energy ball milling is both a processing 
method to reduce particle size and a route to obtaining of 
metastable materials. Under co-grinding the drugs with excipients, 
particle size reduction is very effective due to dispersion of the 
drug within the carrier and, consequently, reduced particle 
agglomeration. This leads to increasing the release rate of the 
drug.  
 
Ball milling brings about partial or complete amorphization of the 
drug. The amorphous pharmaceuticals are markedly more soluble 
than the crystalline substances, however, during processing or 
storage the amorphous state may spontaneously convert back to 
the crystalline state [10,11]. Under co-grinding with excipient, 
depending on the conditions used, the drug can present as a 
molecular, a crystalline particulate or an amorphous particulate 
dispersion. In most cases, co-grinding the drugs with excipients 
leads to formation of mechanocomposites which are characterized 
by high surface of contacts between the components and the 
special properties at the interface. The formation of the drug - 
carrier complexes at the interface appears to be responsible for the 
stabilization of metastable state of the drug.  
 
In the case of water-soluble polymers, the particles of the drug can 
dissolve into the polymer-rich diffusion layer at a sufficiently 
rapid rate, i.e. carrier-controlled mechanism [12] can be realized, 
or, following the drug-controlled mechanism [12], the drug is 
released as solid particles with improving dissolution due to the 
higher surface area and the possibility of improved wetting and 
decreased agglomeration. Forming hydrogen bonds with a 
polymer, the drug can be released as a molecular complex that 
may be stable in solution or decompose into the components.  
 
When the non-soluble carrier is used, the grafting complexes can 
be formed at the surface of the carrier. This can lead to increasing 
the rate of dissolution of the drug. Sometimes, the decreasing rate 
of dissolution and solubility can be observed probably due to 
formation of strong drug-carrier associates. This may be 
interesting for development of medicinal preparations of 
prolonged action. 
 
In any case, the data obtained showed that ball milling of poorly 
water-soluble drugs with excipients can be useful for modification 
of the drugs and obtaining preparations with improved properties. 
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